Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of May 2007
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12 BGC Centre
28
The Esplanade
Perth
WA 6000
Australia
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
The
document attached as Exhibit 99.1 to this Report on Form 6-K is hereby
incorporated by reference herein and into the following registration statements:
(i) the Registrant's Registration Statement on Form F-3, Registration
No. 333-132776; (ii) the Registrant's Registration Statement on
Form F-3, Registration No. 333-132777; (iii) the Registrant's
Registration Statement on Form F-3, Registration No. 333-135428; (iv)
the Registrant's Registration Statement on Form F-3, Registration
No. 333-141083; and (v) the Registrant's Registration Statement on
Form F-3, Registration No. 333-141091.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Date:
May
1, 2007
PSIVIDA
LIMITED
By:
/s/
Michael J.
Soja
Michael
J. Soja
Vice
President, Finance and Chief Financial Officer
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
ASX
Release: pSivida Announces Board
Change
|
pSivida
Announces Board Change
May
1 2007, 8:30 AM EST
Business
Wire
pSivida
Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI),
today announced that Dr. Roger Aston, who joined the Board as a Non-executive
Director in December 2006 has resigned to focus on other activities including
his role as the CEO of his new Australian based company, HalcyGen
Pharmaceuticals Limited.
Dr.
Aston
was previously a Director and Co-Founder of pSivida and stepped down in 2005
in
order to pursue other activities. Dr. Aston rejoined the pSivida Board in
December 2006 to assist the Company in an important period in its development.
pSivida
Non-executive Chairman, Dr. David Mazzo said, "Dr. Aston has been an important
participant in bringing pSivida into a new phase of development and the Company
thanks Dr. Aston for his significant contribution."
Dr.
Aston
said, "I am satisfied that pSivida is now well placed to capitalize on its
technology and intellectual property base. I believe the Company's existing
partnerships provide a solid long-term foundation for the company to grow its
business."
The
Company wishes Dr. Aston good luck with his new venture.
NOTES
TO
EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products. Retisert(R) is FDA approved for the
treatment of uveitis. Vitrasert(R) is FDA approved for the treatment of
AIDS-related CMV Retinitis. Bausch & Lomb owns the trademarks Vitrasert(R)
and Retisert(R). pSivida has licensed the technologies underlying both of these
products to Bausch & Lomb. The technology underlying Medidur(TM) for
diabetic macular edema is licensed to Alimera Sciences and is in Phase III
clinical trials. pSivida has a worldwide collaborative research and license
agreement with Pfizer Inc. for other ophthalmic applications of the Medidur(TM)
technology.
pSivida
owns the rights to develop and commercialize a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon(TM), which has
applications in drug delivery, wound healing, orthopedics, and tissue
engineering. The most advanced BioSilicon(TM) product, BrachySil(TM) delivers
a
therapeutic, P32 directly to solid tumors and is presently in Phase II clinical
trials for the treatment of pancreatic cancer.
pSivida's
intellectual property portfolio consists of 71 patent families, 99 granted
patents, including patents accepted for issuance, and over 300 patent
applications. pSivida conducts its operations from facilities near Boston in
the
United States, Malvern in the United Kingdom and Perth in Australia.
pSivida
is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and on the
Frankfurt Stock Exchange on the XETRA system (PSI). pSivida is a founding member
of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology Index.
This
release contains forward-looking statements that involve risks and
uncertainties, including the risk that we will not be able to capitalize on
our
technology and intellectual property base or grow our business; the risk that
we
may not meet any of the milestones in the Pfizer agreement or may not
successfully develop or commercialize the products under development; the risk
that Pfizer terminates the license agreement; the risk that we will not be
able
to exploit our drug delivery technologies outside of the eye; the risk that
our
evaluation agreements for our products may not produce favorable results and/or
result in license agreements; and the risk that we will be unable to repay
all
amounts outstanding under our convertible notes or other liabilities. Although
we believe that the expectations reflected in such forward-looking statements
are reasonable at this time, we can give no assurance that such expectations
will prove to be correct. Given these uncertainties, readers are cautioned
not
to place undue reliance on such forward-looking statements. Actual results
could
differ materially from those anticipated in these forward-looking statements
due
to many important that are contained in cautionary statements in the Annual
Report on Form 20-F filed with the U.S. Securities and Exchange Commission,
including, without limitation, under Item 3.D, "Risk Factors" therein. We do
not
undertake to update any oral or written forward-looking statements that may
be
made by or on behalf of pSivida.